Ionis to present at the Cowen Annual Health Care Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
Guggenheim Starts Ionis Pharmaceuticals (IONS) at Buy
March 1, 2022 8:18 AM ESTGuggenheim analyst Debjit Chattopadhyay initiates coverage on Ionis Pharmaceuticals (NASDAQ: IONS) with a Buy rating and a price target of $64.00.
The analyst commented, "We are initiating coverage of IONS with a BUY rating. While the platform has had its fair share... More
